Blood Cancers

>

Latest News

Image of blood.
Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

June 5th 2025

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.

Image of blood cells.
Improving Education and Advocacy in Waldenström Macroglobulinemia

May 27th 2025

Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles: ©  stock.adobe.com
Understanding the Use of Bispecific Antibodies in Multiple Myeloma

April 4th 2025

Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
The Positivity Trap of Follicular Lymphoma and Cancer

March 31st 2025

Itolizumab did not improve response rates at Day 29 in acute GVHD; however, the therapy showed significant benefits in long-term outcomes: © stock.adobe.com
Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025

Video Series
Video Interviews
Podcasts
Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

More News